Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: A tyrosine kinase inhibitor withdrawal syndrome?

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2821-2823

  Richter, Johan ^a   Söderlund, Stina ^b   Lübking, Anna ^a   Dreimane, Arta ^c   Lotfi, Kourosh ^c   Markevärn, Berit ^d   Själander, Anders ^e   Saussele, Susanne ^f   Olsson Strömberg, Ulla ^b   Stenke, Leif ^g  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Advanced Center of Translational Regenerative Medicine   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE; IMATINIB; LACTATE DEHYDROGENASE; PREDNISOLONE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; HUMAN; LETTER; MUSCULOSKELETAL PAIN; PRIORITY JOURNAL; WITHDRAWAL SYNDROME; ANTAGONISTS AND INHIBITORS; FEMALE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84906807375     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.6910     Document Type: Letter

References (5)

1. Rousselot P, Charbonnier A, Cony-Makhoul P, et al: Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424-430, 2014
2. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 362:2260-2270, 2010
3. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 362:2251-2259, 2010
4. Breccia M, Alimena G: The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Leuk Res 33:871-875, 2009
5. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000